Akari Therapeutics ADR (AKTX) Stock Price, Quote & News

Company Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads in...

Industry: Biotechnology

Sector: Healthcare

Phone: 929 274 7510

Fax: 929 274 7553

Website: www.akaritx.com

Address:

22 Boston Wharf Road, Floor 7, Boston, United States

Radek93 Jun. 10 at 6:55 PM

$AKTX

0 · Reply

StockTwitsNinja Jun. 4 at 4:38 PM

$AKTX Why did I invest in this shit. WHY

0 · Reply

PennyStocksMom May. 28 at 7:18 PM

⌛️⏳️ Potential swing ideas 💡 ✅️ $AKTX company specializing in the development of next-generation precision bi-functional antibody-drug conjugates (ADCs) for cancer treatment, lead candidate, AKTX-101, upcoming catalysts: 1) preclinical data presentation 2nd half 2025, 2) expanding preclinical studies to explore AKTX,101's's efficacy in various solid tumor indications, including prostate and lung cancers, 3) company exploring research collaborations, 4) participating in ASCO Annual Meeting from May 30 to June 3 in Chicago, 4) Live webinar on $BULL this Thursday 5/29 pm EST to discuss pipelines and upcoming catalysts ✅️ $SONM small float, recently announced new products set to launch in North America, EMEA, and Australia, 3 products in Q2 in North America, company is a leading US provider of rugged mobile solutions 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

0 · Reply

coachmc May. 16 at 11:42 PM

$AKTX absolute turd. Opportunities for a tech move up, but no news ever to reinforce it. Maybe next decade something will happen

1 · Reply

Teo_j May. 5 at 4:00 PM

$AKTX get ready

1 · Reply

coachmc May. 5 at 2:51 PM

$AKTX golden cross??

1 · Reply

StockTwitsNinja Apr. 29 at 4:19 PM

$AKTX

0 · Reply

MTN Apr. 23 at 9:30 PM

$AKTX if they can close a proper partnership, looking at a strong valuation to push the company forward. I'm hoping they really are hyper focused on closing on one indication. That will allow them to start thinking bigger on other parts of the pipeline.

0 · Reply

jennybaby Apr. 23 at 3:31 PM

$AKTX good volume the last couple of days. Now let’s break $1.53 and never look back!

1 · Reply

dan16 Apr. 22 at 7:23 PM

$AKTX https://www.akaritx.com/2025/04/22/welcome-from-abizer-gaslightwala-president-and-ceo/

0 · Reply

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

May 22, 2025, 9:00 AM EDT - 25 days ago

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 19, 2025, 8:00 AM EDT - 4 weeks ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

CRBP QURE

May 15, 2025, 8:05 AM EDT - 4 weeks ago

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 1, 2025, 8:45 AM EDT - 6 weeks ago

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

Apr 22, 2025, 9:05 AM EDT - 7 weeks ago

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Mar 20, 2025, 8:35 AM EDT - 3 months ago

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Mar 3, 2025, 9:00 AM EST - 3 months ago

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Feb 19, 2025, 9:00 AM EST - 4 months ago

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 3, 2025, 8:00 AM EST - 4 months ago

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Dec 18, 2024, 8:51 AM EST - 6 months ago

Akari Therapeutics Announces Key Leadership Appointments

Dec 16, 2024, 9:05 AM EST - 6 months ago

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Nov 14, 2024, 4:15 PM EST - 7 months ago

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Nov 8, 2024, 8:00 AM EST - 7 months ago

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Aug 19, 2024, 4:15 PM EDT - 10 months ago

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 19, 2024, 8:00 AM EDT - 10 months ago

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

May 16, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

May 1, 2024, 8:01 AM EDT - 1 year ago

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

May 1, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Apr 1, 2024, 6:30 AM EDT - 1 year ago

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Mar 5, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Jan 2, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Dec 14, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics to Present at Biotech Showcase 2024

Dec 1, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D.

Nov 16, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Nov 6, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Sep 29, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Sep 27, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Present at Emerging Growth Conference

Sep 21, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aug 18, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

Aug 15, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics, Plc Announces ADS Ratio Change

Aug 2, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

Jul 27, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Jul 19, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

Jul 13, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Jul 11, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation

Jul 5, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Appoints Industry Veteran Wa'el Hashad to Board of Directors

May 16, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Participate in A.G.P.'s Virtual Healthcare Conference

May 1, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights

Apr 25, 2023, 4:15 PM EDT - 2 years ago

Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement

Apr 14, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs

Apr 11, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology

Apr 3, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting

Mar 30, 2023, 9:09 AM EDT - 2 years ago

Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering

Mar 29, 2023, 8:00 AM EDT - 2 years ago

Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study

Radek93 Jun. 10 at 6:55 PM

$AKTX

0 · Reply

StockTwitsNinja Jun. 4 at 4:38 PM

$AKTX Why did I invest in this shit. WHY

0 · Reply

PennyStocksMom May. 28 at 7:18 PM

0 · Reply

coachmc May. 16 at 11:42 PM

$AKTX absolute turd. Opportunities for a tech move up, but no news ever to reinforce it. Maybe next decade something will happen

1 · Reply

Teo_j May. 5 at 4:00 PM

$AKTX get ready

1 · Reply

coachmc May. 5 at 2:51 PM

$AKTX golden cross??

1 · Reply

StockTwitsNinja Apr. 29 at 4:19 PM

$AKTX

0 · Reply

MTN Apr. 23 at 9:30 PM

0 · Reply

jennybaby Apr. 23 at 3:31 PM

$AKTX good volume the last couple of days. Now let’s break $1.53 and never look back!

1 · Reply

dan16 Apr. 22 at 7:23 PM

$AKTX https://www.akaritx.com/2025/04/22/welcome-from-abizer-gaslightwala-president-and-ceo/

0 · Reply

dan16 Apr. 22 at 6:58 PM

$AKTX new CEO as of yesterday. Maybe he's really on the ball or did some pre-work. Wishful thinking.

0 · Reply

Bart69 Apr. 22 at 6:41 PM

$AKTX Well, thanks for "looking out for us" and halted the F stock on the upswing.

0 · Reply

dartgator Apr. 22 at 6:37 PM

$AKTX hmm what was that all about?

0 · Reply

Nick1971 Apr. 22 at 6:32 PM

$AKTX it’s now suspended on WeBull

0 · Reply

Bart69 Apr. 22 at 6:30 PM

$AKTX Oh boy. Hopefully big news.

0 · Reply

HaltTradeAlert Apr. 22 at 6:29 PM

$AKTX Halt Time: 14:26:45 Issue Symbol: AKTX Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!

0 · Reply

StockTwitsNinja Apr. 22 at 6:29 PM

$AKTX I like this spike. Take it to 5

0 · Reply

halted_stocks Apr. 22 at 6:28 PM

0 · Reply

MTN Apr. 17 at 3:38 PM

$AKTX they are focused on partnering, large pipeline previously but they never got to a partner. I'm glad they've narrowed the pipeline down and are now shopping different indications so that they can expand - that is the only way to do it. They have the right team in place - get it done.

0 · Reply

dan16 Apr. 17 at 2:47 PM

$AKTX new CEO starts on Monday. Hopefully, things start moving in the right direction.

0 · Reply

richeey Apr. 16 at 1:06 PM

$AKTX what happened to the eye program?

0 · Reply

DARKP00L Apr. 16 at 12:08 PM

$AKTX 08:07 on Apr. 16 2025 Akari Therapeutics FY24 Net Loss From Operations $21.6M vs $16.8M YoY #tradeideas

0 · Reply

Market Cap	38.29M
Revenue (ttm)	0.00
Net Income (ttm)	-19.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.03

Volume	44,670
Avg Vol	23,614
Day's Range	N/A - N/A
Shares Out	32.18M
Stochastic %K	34%
Beta	0.25
Analysts	Strong Sell
Price Target	$7.00